URGN

Insider Trades

Name	Value	Action	Price	Current Price
Schoenberg MarkChief Medical Officer $350k10k shares SellJun 22, 2026 $35.01 $35.42
Schoenberg MarkChief Medical Officer $67k5.2k shares SellJun 10, 2024 $13.08 --
Smith Jason DrewGeneral Counsel $20k1.5k shares SellSep 9, 2024 $13.08 --
Schoenberg MarkChief Medical Officer $11k859 shares SellSep 9, 2024 $13.08 --
Smith Jason DrewGeneral Counsel $14k1.3k shares SellJan 31, 2025 $11.14 --
Smith Jason DrewGeneral Counsel $37k3.4k shares SellJan 31, 2025 $11.14 --

News

fool.comIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?fool.comJun 14

seekingalpha.comUroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 10

globenewswire.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 5

globenewswire.comUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionglobenewswire.comJun 2

globenewswire.comUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comJun 1

Trade URGN

About UroGen Pharma Ltd.

UroGen Pharma Ltd. is a biotechnology firm dedicated to creating and marketing innovative treatments for specialized cancers and diseases affecting the urinary tract. Its proprietary technology includes RTGel, a biocompatible polymer with reverse thermal gelation properties designed to enhance the efficacy of existing medications. The company also markets Jelmyto, used in pyelocalyceal solutions. A key component of its pipeline is UGN-102, currently undergoing Phase III clinical trials. This investigational drug targets various forms of non-muscle invasive urothelial cancer, specifically low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Additionally, UroGen is developing UGN-301 for high-grade non-muscle invasive bladder cancer. The company holds a licensing agreement with Allergan Pharmaceuticals International Limited, enabling the development and commercialization of pharmaceutical products incorporating both RTGel and clostridial toxins. It also partners with Agenus Inc. to advance, produce, and commercialize Agenus's products for intravesical delivery in urinary tract cancer treatment. Furthermore, a strategic research collaboration with MD Anderson aims to progress experimental treatments for high-grade bladder cancer. Established in 2004, UroGen Pharma Ltd. operates out of Princeton, New Jersey.

CEO: Elizabeth A. Barrett
IPO Date: May 4, 2017

Market Data

Open: $33.37
High: $33.79
Low: $32.21
Volume: 834.8K
Avg Volume: 788.5K
52W High: $33.79
52W Low: $12.73

Valuation

Market Cap: $1.6B
Enterprise Value: $1.7B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-163M
Revenue: $110M
Net Income: $-153M
Cash: $111M
Debt: $128M

Events

EarningsAug 6

EPS est. -0.30375